<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Pediatric Health Med Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">Pediatric Health Med Ther</journal-id>
<journal-id journal-id-type="publisher-id">PHMT</journal-id>
<journal-id journal-id-type="pmc">pedhlth</journal-id>
<journal-title-group>
<journal-title>Pediatric Health, Medicine and Therapeutics</journal-title>
</journal-title-group>
<issn pub-type="epub">1179-9927</issn>
<publisher>
<publisher-name>Dove</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32440248</article-id>
<article-id pub-id-type="pmc">7211084</article-id>
<article-id pub-id-type="publisher-id">198656</article-id>
<article-id pub-id-type="doi">10.2147/PHMT.S198656</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Biotinidase Deficiency: Prevalence, Impact And Management Strategies</article-title>
<alt-title alt-title-type="running-authors">Canda et al</alt-title>
<alt-title alt-title-type="running-title">Canda et al</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Canda</surname>
<given-names>Ebru</given-names>
</name>
<xref ref-type="corresp" rid="AN0001"></xref>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kalkan Uçar</surname>
<given-names>Sema</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-6494-9539</contrib-id>
<name>
<surname>Çoker</surname>
<given-names>Mahmut</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<aff id="AFF0001"><label>1</label><institution>Department of Pediatrics, Faculty of Medicine, Ege University</institution>, <addr-line>Izmir</addr-line>, <country>Turkey</country></aff>
</contrib-group>
<author-notes>
<corresp id="AN0001">Correspondence: Ebru Canda <institution>Department of Pediatrics, Faculty of Medicine, Ege University</institution>, <addr-line>Izmir</addr-line><addr-line>35040</addr-line>, <country>Turkey</country><phone>Tel + 90 232 390 1293</phone> Email ebru.canda@gmail.com</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>04</day>
<month>5</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>11</volume>
<fpage>127</fpage>
<lpage>133</lpage>
<history>
<date date-type="received">
<day>30</day>
<month>9</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>2</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 Canda et al.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Canda et al.</copyright-holder>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
<license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<title>Abstract</title>
<p>Biotinidase deficiency is an autosomal recessive inherited neurocutaneous disorder. Clinically untreated patients with BD can present with variable neurological and dermatological signs, such as seizures, hypotonia, feeding problems, developmental delay, hearing loss, optic atrophy ataxia, alopecia, and skin rash. Clinical findings of patients with partial BD reported in the literature show that it can occur from infancy to adulthood. Outcomes of newborn screening programs support the fact that biotin treatment started after birth prevents patients with biotinidase deficiency from developing symptoms. Presence of late-onset cases with different clinical findings indicates that there is still much to learn about BD.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>biotinidase</kwd>
<kwd>biotin</kwd>
<kwd>newborn screening</kwd>
</kwd-group>
<counts>
<fig-count count="2"></fig-count>
<ref-count count="63"></ref-count>
<page-count count="7"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec id="S0001" sec-type="intro">
<title>Introduction</title>
<p>Biotinidase (EC 3.5.1.12) is the enzyme that cleaves the vitamin, biotin, from the biocytin and from the dietary protein-bound sources, thereby recycling the biotin.<xref ref-type="bibr" rid="CIT0001">1</xref> Free biotin can directly enter the biotin pool and is used by four carboxylases to convert their active forms. Biotin is the coenzyme for four carboxylases that have roles in gluconeogenesis, the catabolism of several branch-chain amino acids and fatty acid synthesis.<xref ref-type="bibr" rid="CIT0002">2</xref>,<xref ref-type="bibr" rid="CIT0003">3</xref> Biotinidase deficiency (BTD) is an autosomal recessive inherited neurocutaneous disorder.<xref ref-type="bibr" rid="CIT0001">1</xref>,<xref ref-type="bibr" rid="CIT0004">4</xref> In BTD all the mitochondrial carboxylase activities become deficient. Deficient activity of pyruvate carboxylase results in the accumulation of lactic acid and alanine. Deficient activity in propionyl-CoA carboxylase results in the accumulation of propionate, 3-OH propionate, and methyl citrate. The accumulation of 3-methylcrotonylglycine and 3-hydoxyisolerate detected is due to the deficient 3-methylcrotonyl-CoA carboxylase enzyme activity. The fourth deficient carboxylase is acetyl CoA carboxylase.<xref ref-type="bibr" rid="CIT0005">5</xref> Since 1982 almost all individuals with juvenile or late-onset form of multiple carboxylase deficiency have been described to have biotinidase deficiency.<xref ref-type="bibr" rid="CIT0001">1</xref> Patients with biotinidase deficiency with less than 10% mean normal serum enzyme activity are classified as having profound deficiency and those with 10–30% mean normal serum activity are classified as having partial deficiency.<xref ref-type="bibr" rid="CIT0006">6</xref></p>
<sec id="S0001-S2001">
<title>Incidence</title>
<p>The incidence of BTD varies from 1:40,000 to 1:60,000 births in the world. In some countries such as Turkey and Saudi Arabia the prevalence is higher due to the high consanguinity rates.<xref ref-type="bibr" rid="CIT0006">6</xref>–<xref ref-type="bibr" rid="CIT0009">9</xref> Based on the newborn screening outcome data from 2006, the incidence of profound BTD in United States is 1:80,000 births and partial deficiency between 1:31,000 and 1:40,000.<xref ref-type="bibr" rid="CIT0010">10</xref> The disease incidence varies between countries; BTD incidence is high in Brazil (1:9000).<xref ref-type="bibr" rid="CIT0011">11</xref> The national newborn screening program in Turkey revealed high incidence. Based on published data from Ministry of Health, the incidence is approximately 1:7,116.<xref ref-type="bibr" rid="CIT0012">12</xref></p>
</sec>
<sec id="S0001-S2002">
<title>Clinical Findings</title>
<p>Clinically untreated patients with BTD can present with variable neurological, dermatological signs; such as seizures, hypotonia, feeding problems, developmental delay, hearing loss, optic atrophy ataxia, alopecia, skin rash.<xref ref-type="bibr" rid="CIT0013">13</xref> Cutaneous manifestations include skin rash, eczema, alopecia, conjunctivitis, viral and fungal infections due to immunological disfunction.<xref ref-type="bibr" rid="CIT0014">14</xref> Scaly erythematous plaques over the flexors and perioral areas and seborrheic dermatitis-like eruptions can be detected. In severe cases crusting, lichenification, and open lesions that may become secondary infections can be seen. Abnormalities in lipid metabolism and alterations in the skin’s composition may play a role in cutaneous manifestations in BTD patients.<xref ref-type="bibr" rid="CIT0015">15</xref>
<xref ref-type="fig" rid="F0001">Figure 1</xref> shows seborrheic dermatitis-like eruptions in a newborn with BTD.<fig fig-type="figure" id="F0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Seborrheic dermatitis-like eruptions in a newborn with biotinidase deficiency.</p></caption><graphic content-type="print-only" xlink:href="PHMT-11-127-g0001"></graphic></fig></p>
<p>Sometimes symptoms can mimic primary immune deficiencies.<xref ref-type="bibr" rid="CIT0016">16</xref> Due to immunologic dysfunction, recurrent viral or fungal infections can be seen. Respiratory problems such as hyperventilation, stridor, and apnea can be detected. Some children with BD manifest a single symptom, sometimes present with multiple neurological and cutaneous findings.<xref ref-type="bibr" rid="CIT0017">17</xref> Symptoms of BTD can be improved or prevented with pharmacological doses of oral biotin. However, if auditory and visual defects occur, they usually persist despite oral biotin therapy.<xref ref-type="bibr" rid="CIT0018">18</xref> If children with profound BTD detected with newborn screening are treated with biotin soon after birth, hearing loss can be prevented.<xref ref-type="bibr" rid="CIT0006">6</xref>,<xref ref-type="bibr" rid="CIT0010">10</xref> The onset of symptoms varies from 2 weeks to 2 years of age but some patients develop symptoms of the disease much later in life.<xref ref-type="bibr" rid="CIT0017">17</xref>,<xref ref-type="bibr" rid="CIT0019">19</xref> Approximately 76% of untreated patients with profound deficiency have sensorineural hearing loss.<xref ref-type="bibr" rid="CIT0020">20</xref></p>
<p>Patients with profound BTD develop symptoms of the disease at an early age.<xref ref-type="bibr" rid="CIT0018">18</xref> If affected patients are not treated with biotin, metabolic decompensation, coma or death can occur.<xref ref-type="bibr" rid="CIT0021">21</xref> The most common neurological symptoms of patients with untreated profound deficiency are seizures and hypotonia.<xref ref-type="bibr" rid="CIT0017">17</xref> Patients with partial BTD usually have milder symptoms. The disease can be misdiagnosed in children with developmental delay and autism.<xref ref-type="bibr" rid="CIT0022">22</xref> In rare cases that are not under treatment, stress might trigger developmental symptoms such as hypotonia, skin rash, and hair loss.<xref ref-type="bibr" rid="CIT0014">14</xref>,<xref ref-type="bibr" rid="CIT0017">17</xref>,<xref ref-type="bibr" rid="CIT0023">23</xref></p>
<p>Clinical findings of patients with partial BTD reported in the literature show that it can occur from infancy to adulthood. The symptoms range from minor symptoms such as rash and alopecia to hypotonia to seizures and developmental delay. Some symptoms may be irreversible even under biotin treatment, as we see in profound BTD.<xref ref-type="bibr" rid="CIT0024">24</xref></p>
<p>Seizure is a frequent symptom in patients with profound BTD. Venkatarman et al reported seizure as the presenting symptom of their case series and clonic seizure was predominant.<xref ref-type="bibr" rid="CIT0025">25</xref> Canda et al detected seizure in three of twelve symptomatic patients with BD, however most of their patients were diagnosed by newborn screening. Today patients are diagnosed early by newborn screening. They are treated with oral biotin. Due to this fact we do not see symptomatic patients frequently.<xref ref-type="bibr" rid="CIT0026">26</xref> Salbert et al detected that forty-three of 78 (55%) symptomatic children had seizures, and seizures were the presenting symptom in 38% of the enzyme-deficient patients in their study.<xref ref-type="bibr" rid="CIT0027">27</xref> BTD results in an absence of recycling of biotin with subsequent impairments of the main biotin-dependent carboxylases and accumulation of potentially neurotoxic and epileptogenic metabolites.<xref ref-type="bibr" rid="CIT0028">28</xref> In vitro studies in BTD fibroblast revealed that low biotin impairs the function of holocarboxylase synthase (HCS) and the transcription of the HCS gene.<xref ref-type="bibr" rid="CIT0029">29</xref> Low biotin levels, toxic metabolites such as organic acids, lactic acid, biocytin, and hyperammonemia may be responsible for different neurological abnormalities in BTD patients.<xref ref-type="bibr" rid="CIT0005">5</xref></p>
<p>Salbert et al found ophthalmic abnormalities in 51% of 78 symptomatic patients with BTD. These findings included 30% infections, 13% optic neuropathies, 13% motility disturbances, 4% retinal pigment changes, and 1% pupillary findings.<xref ref-type="bibr" rid="CIT0027">27</xref> Hayati et al summarized ocular signs of patients published form 1997 to 2011 in PubMed and reported that 6 patients presented with optic atrophy in both eyes.<xref ref-type="bibr" rid="CIT0030">30</xref></p>
<p>Neuromyelitis optica spectrum disorders (NMOSDs) are a group of demyelinating diseases of the central nervous system which essentially involve the optic nerves and spinal cord. In the literature, NMOSD cases were diagnosed with biotinidase deficiency.<xref ref-type="bibr" rid="CIT0031">31</xref>–<xref ref-type="bibr" rid="CIT0033">33</xref> In the last several years, older adolescents and adults have been identified with profound deficiency who exhibited symptoms of myelitis, spastic paresis, paraplegia with or without retinal abnormalities. Most BTD cases are misdiagnosed as multiple sclerosis, transverse myelitis, myasthenia gravis, neuromyelitis optica, and brainstem encephalitis.<xref ref-type="bibr" rid="CIT0034">34</xref> The late onset of BTD should be kept in mind in patients with myelopathy with or without vision loss even if they had partial response to steroid treatment.<xref ref-type="bibr" rid="CIT0033">33</xref></p>
<p>Also, we know that there are several adult patients with profound BTD who remain asymptomatic without treatment. There is no explanation why these patients remain asymptomatic.<xref ref-type="bibr" rid="CIT0010">10</xref> Similarly, Canda et al reported 15 parents diagnosed with BD (two of them with profound BD) by family screening who were all asymptomatic and they did not have increased intake of dietary biotin. These adults may still be at risk for developing symptoms. It is possible that asymptomatic patients can become symptomatic at any time. Also, presence of asymptomatic patients with profound BTD suggests that there may be epigenetic factors that protect patients from developing symptoms.<xref ref-type="bibr" rid="CIT0006">6</xref>,<xref ref-type="bibr" rid="CIT0026">26</xref>,<xref ref-type="bibr" rid="CIT0035">35</xref> Another explanation for clinical heterogeneity is differences in biotinidase K<sub>m</sub> variants.<xref ref-type="bibr" rid="CIT0036">36</xref>,<xref ref-type="bibr" rid="CIT0037">37</xref> The relationship between clinical symptoms and the severity of biotinidase activity is currently unknown.<xref ref-type="bibr" rid="CIT0008">8</xref>,<xref ref-type="bibr" rid="CIT0038">38</xref></p>
</sec>
<sec id="S0001-S2003">
<title>Diagnosis</title>
<p>Biotinidase activity can be measured in serum, plasma, and also in fibroblasts and leukocytes and other tissue extracts by radioassay.<xref ref-type="bibr" rid="CIT0039">39</xref> The measurement of biotinidase activity in plasma or serum by colorimetric assay is the most frequently used method for the diagnosis of BTD.<xref ref-type="bibr" rid="CIT0001">1</xref> Normal serum biotinidase activity in humans ranges from 4.4 to 10 nmol/min/mL with a mean activity and standard deviation of 7.1 ± 1.2 nmol/min/mL.<xref ref-type="bibr" rid="CIT0004">4</xref></p>
<p>Serum biotinidase activity of carriers may be similar to those with partial BTD, confounding diagnosis based on enzyme analysis.<xref ref-type="bibr" rid="CIT0040">40</xref> Wolf suggested that evaluation of parental biotinidase activity may be helpful.<xref ref-type="bibr" rid="CIT0014">14</xref> Mutation in the BTD gene results in deficient levels of enzyme activity.<xref ref-type="bibr" rid="CIT0041">41</xref> In some cases the enzyme activity does not differentiate partial deficiency from heterozygosity for profound deficiency, and genetic analysis is necessary.<xref ref-type="bibr" rid="CIT0006">6</xref></p>
<p>Biochemically, in untreated patients, metabolic ketoacidosis, lactic acidosis, and/or hyperammonemia can occur. Elevation of 3-hydroxyisovaleric, 3-hydroxypropionic, lactic acid, and 3-methylcrotonylglycine can be detected in urine organic acid analysis.<xref ref-type="bibr" rid="CIT0010">10</xref>,<xref ref-type="bibr" rid="CIT0042">42</xref> In previous reports, it showed that urinary excretion of 3-hydroxyisovaleric acid was an indicator of biotin status.<xref ref-type="bibr" rid="CIT0043">43</xref></p>
</sec>
<sec id="S0001-S2004">
<title>Differential Diagnosis</title>
<p>Clinical features including vomiting, hypotonia, and seizures accompanied by metabolic ketolactic acidosis or mild hyperammonemia can be detected in many inherited metabolic diseases.<xref ref-type="bibr" rid="CIT0017">17</xref> A diet containing raw eggs or protracted parenteral hyperalimentation without biotin supplementation may cause similar clinical findings and should be kept in mind in the differential diagnosis.<xref ref-type="bibr" rid="CIT0014">14</xref> Both biotinidase deficiency and holocarboxylase synthetase deficiency are characterized by deficient activities of the three mitochondrial carboxylases in peripheral blood leukocytes and clinical differentiation is often difficult. Biotinidase activity is normal in holocarboxylase synthetase deficiency.<xref ref-type="bibr" rid="CIT0017">17</xref></p>
<p>Sensorineural hearing loss has many causes. Biotinidase activity should be measured specifically in children with hearing loss who are exhibiting other clinical features consistent with biotinidase deficiency.<xref ref-type="bibr" rid="CIT0017">17</xref></p>
</sec>
<sec id="S0001-S2005">
<title>Genetic Analysis</title>
<p>BTD gene is located on chromosome 3p25 and consists of four exons, with a total length of 1629 base pairs.<xref ref-type="bibr" rid="CIT0044">44</xref>,<xref ref-type="bibr" rid="CIT0045">45</xref> More than 200 mutations have been recognized and it is likely that the list of mutations causing biotinidase deficiency will continue to increase.<xref ref-type="bibr" rid="CIT0046">46</xref> All types of mutations have been found in BTD patients; missense, nonsense, single and multiple nucleotide deletions, single and multiple nucleotide insertions, deletion/insertions, cryptic splice site mutations, and compound allelic mutations.<xref ref-type="bibr" rid="CIT0024">24</xref> Four mutations, c.98_104delinsTCC, p.Q456H, p.R538C, and complex mutation p.D444H/A171T are the most common mutations with BTD, as reported by Hymes et al.<xref ref-type="bibr" rid="CIT0041">41</xref> The first microdeletion of BTD that involves three exons of the gene was reported by Wolf and this deletion results in complete loss of biotinidase enzyme activity. The possibility of a deletion in <italic>BTD</italic> gene must be considered in patients with low enzyme activity which is inconsistent with <italic>BTD</italic> gene analysis.<xref ref-type="bibr" rid="CIT0047">47</xref></p>
<p>It is well known that the spectrum of mutations varies in different countries. A large group of patients with BTD ascertained by newborn and family screening from Turkey showed that common mutations are p.R157H, p.D444H, c.98-104del7ins3, and p.T532M. In this study, nine of the patients who were diagnosed by newborn screening had initial symptoms such as seizures, encephalopathy, and lactic acidemia and a common mutation in this group was c.98_104delinsTCC.<xref ref-type="bibr" rid="CIT0008">8</xref> Similar findings were observed about common mutations in different studies from Turkey.<xref ref-type="bibr" rid="CIT0026">26</xref>,<xref ref-type="bibr" rid="CIT0048">48</xref></p>
<p>The p.A171T:D444H mutation is a common cause of profound BTD in children. This mutation is one of the most common mutations in children diagnosed by newborn screening program in United States.<xref ref-type="bibr" rid="CIT0049">49</xref> Patients carrying homozygote p.D444H mutations have nearly 50% mean serum biotinidase activity in serum.<xref ref-type="bibr" rid="CIT0035">35</xref>,<xref ref-type="bibr" rid="CIT0049">49</xref> Although p.D444H mutation causes a considerable decrease in biotinidase enzyme activity alone, in combination with p. A171H mutations, it results in profound BTD.<xref ref-type="bibr" rid="CIT0049">49</xref> The p.D444H mutation alone causes milder mutation, but in combination with mutation for profound BTD on the other allele, it usually results in partial deficiency.<xref ref-type="bibr" rid="CIT0006">6</xref> There have been several polymorphisms detected, and most are single nucleotide alterations. One variant c.117C&gt;T results in P391S with normal enzyme activity.<xref ref-type="bibr" rid="CIT0041">41</xref></p>
<p>Although genotype-phenotype correlations are not well established in BD, Sivri et al reported that children with profound BD with null mutations were more likely to develop hearing loss than those with missense mutations.<xref ref-type="bibr" rid="CIT0050">50</xref></p>
<p>After detecting a patient with BD, genetic counseling should be done. To evaluate the relatives at risk, measurement of biotinidase enzyme activity and molecular genetic testing should be performed.</p>
</sec>
<sec id="S0001-S2006">
<title>Radiological Findings</title>
<p>Cerebral atrophy, ventriculomegaly, widened extra cerebral spaces, subdural effusions, basal ganglion calcifications and T2 hyperintensities were the findings of brain imaging in BTD patients. Bhat et al reported T2 and FLAIR hyperintensities in bilateral hippocampi and para hippocampal gyri as novel observation in BTD patients.<xref ref-type="bibr" rid="CIT0051">51</xref>,<xref ref-type="bibr" rid="CIT0052">52</xref> Spinal cord involvement was described especially in older patients with late onset BTD.<xref ref-type="bibr" rid="CIT0053">53</xref></p>
</sec>
<sec id="S0001-S2007">
<title>Treatment and Management</title>
<p>Patients with profound BTD are treated with 5–20 mg/day biotin. All symptomatic individuals improve clinically with biotin therapy. Seizures usually resolve within hours to days and cutaneous manifestations usually resolve within weeks.<xref ref-type="bibr" rid="CIT0006">6</xref> Oral biotin therapy provides improvement in  symptoms such as alopecia, skin rash, ataxia, and developmental delay.<xref ref-type="bibr" rid="CIT0013">13</xref></p>
<p>As the child grows the quantity of biotin administration decreases. Some have monitored urine organic acid to control whether the dosage of biotin is enough.<xref ref-type="bibr" rid="CIT0006">6</xref> Treatment of partial BTD was initially controversial but over the years, due to the presence of symptomatic partial BTD patients who were not screened and presence of untreated patients who developed symptoms, treatment of partial BTD patients is also recommended.<xref ref-type="bibr" rid="CIT0026">26</xref></p>
<p>Symptomatic children often have developmental delay and are at risk of irreversible damage to auditory, visual, or central nervous system functions. Children with profound BTD who were diagnosed pre-symptomatically following newborn screening and treated with biotin supplementation, do not experience these effects.<xref ref-type="bibr" rid="CIT0054">54</xref> Based on mutation analysis and biotinidase enzyme activity, it is currently not clear whether an untreated patient will develop symptoms or not. The patients with activities lower than 1% are at a high risk for developing symptoms of the disease.<xref ref-type="bibr" rid="CIT0055">55</xref></p>
<p>Wolf at el recommend that the children with both profound and partial BTD should be monitored for hearing loss periodically (yearly in profound BD, every two years in partial BD).<xref ref-type="bibr" rid="CIT0006">6</xref> Also, children with BD should be evaluated for psychomotor deficit, and have ophthalmologic examination (yearly in profound BD, every two years in partial BD) and physical examination for neurological abnormalities, cutaneous findings and infections.<xref ref-type="bibr" rid="CIT0029">29</xref> In the literature, two girls with profound BD developed hair-loss during adolescence that was resolved by increasing the dose of biotin.<xref ref-type="bibr" rid="CIT0029">29</xref> We need more data to determine the dosage of biotin that is necessary for children with BD. Measurement of blood or urine biotin levels is not useful. Also, it can determine compliance with treatment. Evaluation of urine organic acid analysis can be performed if the symptoms return after treatment.<xref ref-type="bibr" rid="CIT0029">29</xref></p>
<p>Biotin is considered safe and non-toxic even in high concentrations. This fact brought a specific problem to medical practitioners' attention.<xref ref-type="bibr" rid="CIT0056">56</xref> Most clinical immunoassays that measure analytics in small concentrations, such as hormones, use specific and sensitive biotin (avidin) technologies.<xref ref-type="bibr" rid="CIT0057">57</xref></p>
<p>High concentrations of biotin in the samples caused incorrect abnormal results. Biotin use can result in false high levels of T3 and T4 and false low TSH levels leading to wrong diagnosis of hyperthyroidism. It should be kept in mind during follow-up.<xref ref-type="bibr" rid="CIT0058">58</xref></p>
</sec>
<sec id="S0001-S2008">
<title>Newborn- Screening</title>
<p>The first newborn screening program for BTD was initiated in Virginia in 1984.<xref ref-type="bibr" rid="CIT0059">59</xref> Determination of biotinidase activity on dried blood samples was first used in a pilot study program in Virginia. BTD screening is performed by direct immune assay and results are not related to dietary protein intake. There has been a high rate of false positive results due to prematurity and mishandling of samples.<xref ref-type="bibr" rid="CIT0010">10</xref>,<xref ref-type="bibr" rid="CIT0060">60</xref> Wolf at el showed that biotinidase activity is between 50–70% of adult serum biotinidase activity in term infants.<xref ref-type="bibr" rid="CIT0006">6</xref>,<xref ref-type="bibr" rid="CIT0061">61</xref> The enzyme activity reaches adult levels in days to weeks.<xref ref-type="bibr" rid="CIT0022">22</xref> Neonatal screening for BTD is conducted in many countries. In Turkey BD screening has been included in neonatal screening program since 2008.<xref ref-type="bibr" rid="CIT0008">8</xref></p>
<p>False positive results can be detected if the patient has above normal albumin levels or if the patient is being treated with valproic acid or has high triglyceride levels. If an individual is being treated with sulfa medications, false negative results can occur when biotinyl-6-aminoquinoline was used for substrate, fortunately sulfa medications are contraindicated in pregnant women and infants.<xref ref-type="bibr" rid="CIT0014">14</xref></p>
<p>Outcomes of newborn screening programs support the fact that biotin treatment started after birth prevents patients with BTD from developing symptoms. There has not been much time between the first description of the disease and newborn BTD screening programs and due to this fact there is a lack of information about long-term natural history of the disorder.<xref ref-type="bibr" rid="CIT0062">62</xref>,<xref ref-type="bibr" rid="CIT0063">63</xref></p>
</sec>
</sec>
<sec id="S0002">
<title>Conclusion</title>
<p>Biotinidase deficiency is an excellent example of early detection and successful treatment of an inherited metabolic disorder. Symptomatic patients with BD can be easily treated with biotin. Today most patients diagnosed by newborn screening are treated with biotin at early ages and due to this fact the number of asymptomatic patients is increasing. Presence of late-onset cases with different clinical findings indicates that there is still much to learn about BD. By the increasing number of patients with BD and detection of many mutations in BTD gene we expect to have more information about genotype and phenotype correlation.</p>
</sec>
</body>
<back>
<sec id="S0003" sec-type="COI-statement">
<title>Disclosure</title>
<p>The authors report no conflicts of interest in this work.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="CIT0001">
<label>1.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Grier</surname>
<given-names>RE</given-names></string-name>, <string-name><surname>Allen</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Goodman</surname>
<given-names>SI</given-names></string-name>, <string-name><surname>Kien</surname>
<given-names>CL</given-names></string-name>. <article-title>Biotinidase deficiency: the enzymatic defect in late-onset multiple carboxylase deficiency</article-title>. <source/><italic toggle="yes">Clin Chim Acta</italic>. <year>1983</year>;<volume>131</volume>(<issue>3</issue>):<fpage>273</fpage>–<lpage>281</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0009-8981(83)90096-7</pub-id><pub-id pub-id-type="pmid">6883721</pub-id></mixed-citation>
</ref>
<ref id="CIT0002">
<label>2.</label>
<mixed-citation publication-type="journal"><string-name><surname>Moss</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lane</surname>
<given-names>MD</given-names></string-name>.<article-title>The biotin-dependent enzymes</article-title>. <source/><italic toggle="yes">Adv Enzymol Relat Areas Mol Biol</italic>.<year>1971</year>;<volume>35</volume>:<fpage>321</fpage>–<lpage>442</lpage>. doi:<pub-id pub-id-type="doi">10.1002/9780470122808.ch7</pub-id><pub-id pub-id-type="pmid">4150153</pub-id></mixed-citation>
</ref>
<ref id="CIT0003">
<label>3.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Hsia</surname>
<given-names>YE</given-names></string-name>, <string-name><surname>Sweetman</surname>
<given-names>L</given-names></string-name>, et al. <article-title>Multiple carboxylase deficiency: clinical and biochemical improvement following neonatal biotin treatment</article-title>. <source/><italic toggle="yes">Pediatrics</italic>. <year>1981</year>;<volume>68</volume>(<issue>1</issue>):<fpage>113</fpage>–<lpage>118</lpage>.<pub-id pub-id-type="pmid">6787561</pub-id></mixed-citation>
</ref>
<ref id="CIT0004">
<label>4.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Grier</surname>
<given-names>RE</given-names></string-name>, <string-name><surname>Secor McVoy</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Heard</surname>
<given-names>GS</given-names></string-name>. <article-title>Biotinidase deficiency: a novel vitamin recycling defect</article-title>. <source/><italic toggle="yes">J Inherit Metab Dis</italic>. <year>1985</year>;<volume>8</volume>(<issue>Suppl 1</issue>):<fpage>53</fpage>–<lpage>58</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF01800660</pub-id></mixed-citation>
</ref>
<ref id="CIT0005">
<label>5.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <article-title>The neurology of biotinidase deficiency</article-title>. <source/><italic toggle="yes">Mol Genet Metab</italic>. <year>2011</year>;<volume>104</volume>(<issue>1–2</issue>):<fpage>27</fpage>–<lpage>34.Review</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymgme.2011.06.001</pub-id><pub-id pub-id-type="pmid">21696988</pub-id></mixed-citation>
</ref>
<ref id="CIT0006">
<label>6.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <article-title>Clinical issues and frequent questions about biotinidase deficiency</article-title>. <source/><italic toggle="yes">Mol Genet Metab</italic>. <year>2010</year>;<volume>100</volume>(<issue>1</issue>):<fpage>6</fpage>–<lpage>13</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymgme.2010.01.003</pub-id><pub-id pub-id-type="pmid">20129807</pub-id></mixed-citation>
</ref>
<ref id="CIT0007">
<label>7.</label>
<mixed-citation publication-type="book"><string-name><surname>Baumgardner</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Suormala</surname>
<given-names>T.</given-names></string-name>
<chapter-title>Biotin-Responsive Disorders</chapter-title> In: <string-name><surname>Saudubray</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Baumgardner</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Walter</surname>
<given-names>J</given-names></string-name>, editors. <source/><italic toggle="yes">Inborn Metabolic Diseases Diagnosis and Treatment</italic>. <publisher-loc>Heidelberg</publisher-loc>: <publisher-name>Springer-Verlag Berlin Heidelberg</publisher-name>; <year>2016</year>:<fpage>375</fpage><lpage>–383</lpage>.</mixed-citation>
</ref>
<ref id="CIT0008">
<label>8.</label>
<mixed-citation publication-type="journal"><string-name><surname>Karaca</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Özgül</surname>
<given-names>RK</given-names></string-name>, <string-name><surname>Ö</surname>
<given-names>Ü</given-names></string-name>, et al. <article-title>Detection of biotinidase gene mutations in Turkish patients ascertained by newborn and family screening</article-title>. <source/><italic toggle="yes">Eur J Pediatr</italic>. <year>2015</year>;<volume>174</volume>(<issue>8</issue>):<fpage>1077</fpage>–<lpage>1084</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00431-015-2509-5</pub-id><pub-id pub-id-type="pmid">25754625</pub-id></mixed-citation>
</ref>
<ref id="CIT0009">
<label>9.</label>
<mixed-citation publication-type="journal"><string-name><surname>Cowan</surname>
<given-names>TM</given-names></string-name>, <string-name><surname>Blitzer</surname>
<given-names>MG</given-names></string-name>, <string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>, <collab>Working Group of the American College of Medical Genetics Laboratory Quality Assurance Committee</collab>. <article-title>Technical standards and guidelines for the diagnosis of biotinidase deficiency</article-title>. <source/><italic toggle="yes">Genet Med</italic>. <year>2010</year>;<volume>12</volume>(<issue>7</issue>):<fpage>464</fpage>–<lpage>470</lpage>. doi:<pub-id pub-id-type="doi">10.1097/GIM.0b013e3181e4cc0f</pub-id><pub-id pub-id-type="pmid">20539236</pub-id></mixed-citation>
</ref>
<ref id="CIT0010">
<label>10.</label>
<mixed-citation publication-type="journal"><string-name><surname>Strovel</surname>
<given-names>ET</given-names></string-name>, <string-name><surname>Cowan</surname>
<given-names>TM</given-names></string-name>, <string-name><surname>Scott</surname>
<given-names>AI</given-names></string-name>, <string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <article-title>Laboratory diagnosis of biotinidase deficiency, 2017 update: a technical standard and guideline of the American College of Medical Genetics and Genomics</article-title>. <source/><italic toggle="yes">Genet Med</italic>. <year>2017</year>;<volume>19</volume>(<issue>10</issue>):<fpage>Oct</fpage>. doi:<pub-id pub-id-type="doi">10.1038/gim.2017.84</pub-id></mixed-citation>
</ref>
<ref id="CIT0011">
<label>11.</label>
<mixed-citation publication-type="journal"><string-name><surname>Neto</surname>
<given-names>EC</given-names></string-name>, <string-name><surname>Schulte</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rubim</surname>
<given-names>R</given-names></string-name>, et al. <article-title>Newborn screening for biotinidase deficiency in Brazil: biochemical and molecular characterizations</article-title>. <source/><italic toggle="yes">Braz J Med Biol Res</italic>. <year>2004</year>;<volume>37</volume>(<issue>3</issue>):<fpage>295</fpage>–<lpage>299</lpage>. doi:<pub-id pub-id-type="doi">10.1590/S0100-879X2004000300001</pub-id><pub-id pub-id-type="pmid">15060693</pub-id></mixed-citation>
</ref>
<ref id="CIT0012">
<label>12.</label>
<mixed-citation publication-type="journal"><string-name><surname>Baykal</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Hüner</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Sarbat</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Demirkol</surname>
<given-names>M</given-names></string-name>. <article-title>Incidence of biotinidase deficiency in Turkish newborns</article-title>. <source/><italic toggle="yes">Acta Paediatr</italic>. <year>1998</year>;<volume>87</volume>:<fpage>1102</fpage>–<lpage>1103</lpage>. doi:<pub-id pub-id-type="doi">10.1080/080352598750031518</pub-id><pub-id pub-id-type="pmid">9825985</pub-id></mixed-citation>
</ref>
<ref id="CIT0013">
<label>13.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Heard</surname>
<given-names>GS</given-names></string-name>, <string-name><surname>Weissbecker</surname>
<given-names>KA</given-names></string-name>, <string-name><surname>McVoy</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Grier</surname>
<given-names>RE</given-names></string-name>, <string-name><surname>Leshner</surname>
<given-names>RT</given-names></string-name>. <article-title>Biotinidase deficiency: initial clinical features and rapid diagnosis</article-title>. <source/><italic toggle="yes">Ann Neurol</italic>. <year>1985</year>;<volume>18</volume>(<issue>5</issue>):<fpage>614</fpage>–<lpage>617</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.410180517</pub-id><pub-id pub-id-type="pmid">4073853</pub-id></mixed-citation>
</ref>
<ref id="CIT0014">
<label>14.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <article-title>Biotinidase deficiency: “if you have to have an inherited metabolic disease, this is the one to have”</article-title>. <source/><italic toggle="yes">Genet Med</italic>. <year>2012</year>;<volume>14</volume>(<issue>6</issue>):<fpage>565</fpage>–<lpage>575</lpage>. doi:<pub-id pub-id-type="doi">10.1038/gim.2011.6</pub-id><pub-id pub-id-type="pmid">22241090</pub-id></mixed-citation>
</ref>
<ref id="CIT0015">
<label>15.</label>
<mixed-citation publication-type="journal"><string-name><surname>Mock</surname>
<given-names>DM</given-names></string-name>. <article-title>Skin manifestations of biotin deficiency</article-title>. <source/><italic toggle="yes">Semin Dermatol</italic>. <year>1991</year>;<volume>10</volume>(<issue>4</issue>):<fpage>296</fpage>–<lpage>302</lpage>.<pub-id pub-id-type="pmid">1764357</pub-id></mixed-citation>
</ref>
<ref id="CIT0016">
<label>16.</label>
<mixed-citation publication-type="journal"><string-name><surname>Kiykim</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Kiykim</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Cansever</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Zeybek</surname>
<given-names>CA</given-names></string-name>. <article-title>Biotinidase deficiency mimicking primary immune deficiencies</article-title>. <source/><italic toggle="yes">BMJ Case Rep</italic>. <year>2015</year>;<volume>8</volume>:<fpage>2015</fpage>.</mixed-citation>
</ref>
<ref id="CIT0017">
<label>17.</label>
<mixed-citation publication-type="book"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <chapter-title>Biotinidase Deficiency</chapter-title> In: <string-name><surname>Adam</surname>
<given-names>MP</given-names></string-name>, <string-name><surname>Ardinger</surname>
<given-names>HH</given-names></string-name>, <string-name><surname>Pagon</surname>
<given-names>RA</given-names></string-name>, et al. editors. <source/><italic toggle="yes">GeneReviews<sup>®</sup> [Internet]</italic>. <publisher-loc>Seattle</publisher-loc>: <publisher-name>University of Washington</publisher-name>; <year>2000</year>
<month>3</month>
<day>24</day>:<fpage>1993</fpage>–<lpage>2019</lpage>. Available from <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK1322/">http://www.ncbi.nlm.nih.gov/books/NBK1322/</ext-link>. <date-in-citation>updated 2016 <month>6</month><day>9</day></date-in-citation>.</mixed-citation>
</ref>
<ref id="CIT0018">
<label>18.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Spencer</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Gleason</surname>
<given-names>T</given-names></string-name>. <article-title>Hearing loss is a common feature of symptomatic children with profound biotinidase deficiency</article-title>. <source/><italic toggle="yes">J Pediatr</italic>. <year>2002</year>;<volume>140</volume>(<issue>2</issue>):<fpage>242</fpage>–<lpage>246</lpage>. doi:<pub-id pub-id-type="doi">10.1067/mpd.2002.121938</pub-id><pub-id pub-id-type="pmid">11865279</pub-id></mixed-citation>
</ref>
<ref id="CIT0019">
<label>19.</label>
<mixed-citation publication-type="journal"><string-name><surname>Ferreira</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Chan</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <article-title>Irreversibility of symptoms with biotin therapy in an adult with profound biotinidase deficiency</article-title>. <source/><italic toggle="yes">JIMD Rep</italic>. <year>2017</year>;<volume>36</volume>:<fpage>117</fpage>–<lpage>120</lpage>.<pub-id pub-id-type="pmid">28220409</pub-id></mixed-citation>
</ref>
<ref id="CIT0020">
<label>20.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <article-title>Children with profound biotinidase deficiency should be treated with biotin regardless of their residual enzyme activity or genotype</article-title>. <source/><italic toggle="yes">Eur J Pediatr</italic>. <year>2002</year>;<volume>161</volume>(<issue>3</issue>):<fpage>167</fpage>–<lpage>168</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00431-001-0902-8</pub-id><pub-id pub-id-type="pmid">11998918</pub-id></mixed-citation>
</ref>
<ref id="CIT0021">
<label>21.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Grier</surname>
<given-names>RE</given-names></string-name>, <string-name><surname>Allen</surname>
<given-names>RJ</given-names></string-name>, et al. <article-title>Phenotypic variation in biotinidase deficiency</article-title>. <source/><italic toggle="yes">J Pediatr</italic>. <year>1983</year>;<volume>103</volume>(<issue>2</issue>):<fpage>233</fpage>–<lpage>237</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0022-3476(83)80351-5</pub-id><pub-id pub-id-type="pmid">6875714</pub-id></mixed-citation>
</ref>
<ref id="CIT0022">
<label>22.</label>
<mixed-citation publication-type="journal"><string-name><surname>Manzi</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Loizzo</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>Giana</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Curatolo</surname>
<given-names>P</given-names></string-name>. <article-title>Autism and metabolic diseases</article-title>. <source/><italic toggle="yes">J Child Neurol</italic>. <year>2008</year>;<volume>23</volume>(<issue>3</issue>):<fpage>307</fpage>–<lpage>314</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0883073807308698</pub-id><pub-id pub-id-type="pmid">18079313</pub-id></mixed-citation>
</ref>
<ref id="CIT0023">
<label>23.</label>
<mixed-citation publication-type="journal"><string-name><surname>Küry</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ramaekers</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Bézieau</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <article-title>Clinical utility gene card for: biotinidase deficiency-update 2015</article-title>. <source/><italic toggle="yes">Eur J Hum Genet</italic>. <year>2016</year>;<volume>24</volume>(<issue>7</issue>):<fpage>3</fpage>–<lpage>5</lpage>.</mixed-citation>
</ref>
<ref id="CIT0024">
<label>24.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <article-title>Why screen newborns for profound and partial biotinidase deficiency?</article-title>
<source/><italic toggle="yes">Mol Genet Metab</italic>. <year>2015</year>;<volume>114</volume>(<issue>3</issue>):<fpage>382</fpage>–<lpage>387</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymgme.2015.01.003</pub-id><pub-id pub-id-type="pmid">25638506</pub-id></mixed-citation>
</ref>
<ref id="CIT0025">
<label>25.</label>
<mixed-citation publication-type="journal"><string-name><surname>Venkataraman</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Balaji</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Panigrahi</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Jamal</surname>
<given-names>R</given-names></string-name>. <article-title>Biotinidase deficiency in childhood</article-title>. <source/><italic toggle="yes">Neurol India</italic>. <year>2013</year>;<volume>61</volume>(<issue>4</issue>):<fpage>411</fpage>–<lpage>413</lpage>. doi:<pub-id pub-id-type="doi">10.4103/0028-3886.117614</pub-id><pub-id pub-id-type="pmid">24005734</pub-id></mixed-citation>
</ref>
<ref id="CIT0026">
<label>26.</label>
<mixed-citation publication-type="journal"><string-name><surname>Canda</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Yazici</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Er</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Single center experience of biotinidase deficiency: 259 patients and six novel mutations</article-title>. <source/><italic toggle="yes">J Pediatr Endocrinol Metab</italic>. <year>2018</year>;<volume>31</volume>(<issue>8</issue>):<fpage>917</fpage>–<lpage>926</lpage>. doi:<pub-id pub-id-type="doi">10.1515/jpem-2018-0148</pub-id><pub-id pub-id-type="pmid">29995633</pub-id></mixed-citation>
</ref>
<ref id="CIT0027">
<label>27.</label>
<mixed-citation publication-type="journal"><string-name><surname>Salbert</surname>
<given-names>BA</given-names></string-name>, <string-name><surname>Astruc</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <article-title>Ophthalmologic findings in biotinidase deficiency</article-title>. <source/><italic toggle="yes">Ophthalmologica</italic>. <year>1993</year>;<volume>206</volume>(<issue>4</issue>):<fpage>177</fpage>–<lpage>181</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000310387</pub-id><pub-id pub-id-type="pmid">8278163</pub-id></mixed-citation>
</ref>
<ref id="CIT0028">
<label>28.</label>
<mixed-citation publication-type="journal"><string-name><surname>Mastrangelo</surname>
<given-names>M</given-names></string-name>. <article-title>Actual insights into treatable inborn errors of metabolism causing epilepsy</article-title>. <source/><italic toggle="yes">J Pediatr Neurosci</italic>. <year>2018</year>;<volume>13</volume>(<issue>1</issue>):<fpage>13</fpage>–<lpage>23</lpage>. doi:<pub-id pub-id-type="doi">10.4103/JPN.JPN_160_16</pub-id><pub-id pub-id-type="pmid">29899766</pub-id></mixed-citation>
</ref>
<ref id="CIT0029">
<label>29.</label>
<mixed-citation publication-type="journal"><string-name><surname>León-Del-Río</surname>
<given-names>A</given-names></string-name>. <article-title>Biotin in metabolism, gene expression, and human disease</article-title>. <source/><italic toggle="yes">J Inherit Metab Dis</italic>. <year>2019</year>;<volume>42</volume>(<issue>4</issue>):<fpage>647</fpage>–<lpage>654</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jimd.12073</pub-id><pub-id pub-id-type="pmid">30746739</pub-id></mixed-citation>
</ref>
<ref id="CIT0030">
<label>30.</label>
<mixed-citation publication-type="journal"><string-name><surname>Hayati</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>Wan-Hitam</surname>
<given-names>WH</given-names></string-name>, <string-name><surname>Cheong</surname>
<given-names>MT</given-names></string-name>, <string-name><surname>Yunus</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Shatriah</surname>
<given-names>I</given-names></string-name>. <article-title>Optic neuritis in a child with biotinidase deficiency: case report and literature review</article-title>. <source/><italic toggle="yes">Clin Ophthalmol</italic>. <year>2012</year>;<volume>6</volume>:<fpage>389</fpage>–<lpage>395</lpage>. doi:<pub-id pub-id-type="doi">10.2147/OPTH.S29048</pub-id><pub-id pub-id-type="pmid">22457589</pub-id></mixed-citation>
</ref>
<ref id="CIT0031">
<label>31.</label>
<mixed-citation publication-type="journal"><string-name><surname>Girard</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Bonnemains</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Schmitt</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Raffo</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Bilbault</surname>
<given-names>C</given-names></string-name>. <article-title>Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: a treatable disease</article-title>. <source/><italic toggle="yes">Mult Scler</italic>. <year>2017</year>;<volume>23</volume>(<issue>1</issue>):<fpage>119</fpage>–<lpage>122</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1352458516646087</pub-id><pub-id pub-id-type="pmid">27207447</pub-id></mixed-citation>
</ref>
<ref id="CIT0032">
<label>32.</label>
<mixed-citation publication-type="journal"><string-name><surname>Bottin</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Prud’hon</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Guey</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Biotinidase deficiency mimicking neuromyelitis optica: initially exhibiting symptoms in adulthood</article-title>. <source/><italic toggle="yes">Mult Scler</italic>. <year>2015</year>;<volume>21</volume>(<issue>12</issue>):<fpage>1604</fpage>–<lpage>1607</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1352458515596457</pub-id><pub-id pub-id-type="pmid">26203071</pub-id></mixed-citation>
</ref>
<ref id="CIT0033">
<label>33.</label>
<mixed-citation publication-type="journal"><string-name><surname>Yilmaz</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Serin</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Canda</surname>
<given-names>E</given-names></string-name>, et al. <article-title>A treatable cause of myelopathy and vision loss mimicking neuromyelitis optica spectrum disorder: late-onset biotinidase deficiency</article-title>. <source/><italic toggle="yes">Metab Brain Dis</italic>. <year>2017</year>;<volume>32</volume>(<issue>3</issue>):<fpage>675</fpage>–<lpage>678</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11011-017-9984-5</pub-id><pub-id pub-id-type="pmid">28281033</pub-id></mixed-citation>
</ref>
<ref id="CIT0034">
<label>34.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <article-title>“Think metabolic” in adults with diagnostic challenges: biotinidase deficiency as a paradigm disorder</article-title>. <source/><italic toggle="yes">Neurol Clin Pract</italic>. <year>2017</year>;<volume>7</volume>(<issue>6</issue>):<fpage>518</fpage>–<lpage>522</lpage>. doi:<pub-id pub-id-type="doi">10.1212/CPJ.0000000000000379</pub-id><pub-id pub-id-type="pmid">29431165</pub-id></mixed-citation>
</ref>
<ref id="CIT0035">
<label>35.</label>
<mixed-citation publication-type="journal"><string-name><surname>Swango</surname>
<given-names>KL</given-names></string-name>, <string-name><surname>Demirkol</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hüner</surname>
<given-names>G</given-names></string-name>, et al. <article-title>Partial biotinidase deficiency is usually due to the D444H mutation in the biotinidase gene</article-title>. <source/><italic toggle="yes">Hum Genet</italic>. <year>1998</year>;<volume>102</volume>(<issue>5</issue>):<fpage>571</fpage>–<lpage>575</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s004390050742</pub-id><pub-id pub-id-type="pmid">9654207</pub-id></mixed-citation>
</ref>
<ref id="CIT0036">
<label>36.</label>
<mixed-citation publication-type="journal"><string-name><surname>Baykal</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Gokcay</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Gokdemir</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Asymptomatic adults and older siblings with biotinidase deficiency ascertained by family studies of index cases</article-title>. <source/><italic toggle="yes">J Inherit Metab Dis</italic>. <year>2005</year>;<volume>28</volume>(<issue>6</issue>):<fpage>903</fpage>–<lpage>912</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10545-005-0161-3</pub-id><pub-id pub-id-type="pmid">16435182</pub-id></mixed-citation>
</ref>
<ref id="CIT0037">
<label>37.</label>
<mixed-citation publication-type="journal"><string-name><surname>Suormala</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ramaekers</surname>
<given-names>VT</given-names></string-name>, <string-name><surname>Schweitzer</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Biotinidase Km-variants: detection and detailed biochemical investigations</article-title>. <source/><italic toggle="yes">J Inherit Metab Dis</italic>. <year>1995</year>;<volume>18</volume>(<issue>6</issue>):<fpage>689</fpage>–<lpage>700</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF02436758</pub-id><pub-id pub-id-type="pmid">8750606</pub-id></mixed-citation>
</ref>
<ref id="CIT0038">
<label>38.</label>
<mixed-citation publication-type="journal"><string-name><surname>Ye</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>LS</given-names></string-name>, et al. <article-title>Diagnosis, treatment, follow-up and gene mutation analysis in four Chinese children with biotinidase deficiency</article-title>. <source/><italic toggle="yes">J Inherit Metab Dis</italic>. <year>2009</year>;<volume>32</volume>(<issue>Suppl1</issue>):<fpage>S295</fpage>–<lpage>302</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10545-009-1238-1</pub-id><pub-id pub-id-type="pmid">19728141</pub-id></mixed-citation>
</ref>
<ref id="CIT0039">
<label>39.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Secor McVoy</surname>
<given-names>J</given-names></string-name>. <article-title>A sensitive radioassay for biotinidase activity: deficient activity in tissues of serum biotinidase-deficient individuals</article-title>. <source/><italic toggle="yes">Clin Chim Acta</italic>. <year>1983</year>;<volume>135</volume>(<issue>3</issue>):<fpage>275</fpage>–<lpage>281</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0009-8981(83)90286-3</pub-id><pub-id pub-id-type="pmid">6661819</pub-id></mixed-citation>
</ref>
<ref id="CIT0040">
<label>40.</label>
<mixed-citation publication-type="journal"><string-name><surname>Gannavarapu</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Prasad</surname>
<given-names>C</given-names></string-name>, <string-name><surname>DiRaimo</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Biotinidase deficiency: spectrum of molecular, enzymatic and clinical information from newborn screening Ontario, Canada (2007–2014)</article-title>. <source/><italic toggle="yes">Mol Genet Metab</italic>. <year>2015</year>;<volume>116</volume>(<issue>3</issue>):<fpage>146</fpage>–<lpage>151</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymgme.2015.08.010</pub-id><pub-id pub-id-type="pmid">26361991</pub-id></mixed-citation>
</ref>
<ref id="CIT0041">
<label>41.</label>
<mixed-citation publication-type="journal"><string-name><surname>Hymes</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Stanley</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <article-title>Mutations in BTD causing biotinidase deficiency</article-title>. <source/><italic toggle="yes">Hum Mutat</italic>. <year>2001</year>;<volume>18</volume>(<issue>5</issue>):<fpage>375</fpage>–<lpage>381</lpage>. doi:<pub-id pub-id-type="doi">10.1002/(ISSN)1098-1004</pub-id><pub-id pub-id-type="pmid">11668630</pub-id></mixed-citation>
</ref>
<ref id="CIT0042">
<label>42.</label>
<mixed-citation publication-type="journal"><string-name><surname>Schubiger</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Caflisch</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Baumgartner</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Suormala</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Bachmann</surname>
<given-names>C</given-names></string-name>. <article-title>Biotinidase deficiency: clinical course and biochemical findings</article-title>. <source/><italic toggle="yes">J Inherit Metab Dis</italic>. <year>1984</year>;<volume>7</volume>(<issue>3</issue>):<fpage>129</fpage>–<lpage>130</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF01801771</pub-id></mixed-citation>
</ref>
<ref id="CIT0043">
<label>43.</label>
<mixed-citation publication-type="journal"><string-name><surname>Horvath</surname>
<given-names>TD</given-names></string-name>, <string-name><surname>Matthews</surname>
<given-names>NI</given-names></string-name>, <string-name><surname>Stratton</surname>
<given-names>SL</given-names></string-name>, <string-name><surname>Mock</surname>
<given-names>DM</given-names></string-name>, <string-name><surname>Boysen</surname>
<given-names>G</given-names></string-name>. <article-title>Measurement of 3-hydroxyisovaleric acid in urine from marginally biotin-deficient humans by UPLC-MS/MS</article-title>. <source/><italic toggle="yes">Anal Bioanal Chem</italic>. <year>2011</year>;<volume>401</volume>(<issue>9</issue>):<fpage>2805</fpage>–<lpage>2810</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00216-011-5356-x</pub-id><pub-id pub-id-type="pmid">21892638</pub-id></mixed-citation>
</ref>
<ref id="CIT0044">
<label>44.</label>
<mixed-citation publication-type="journal"><string-name><surname>Cole</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Reynolds</surname>
<given-names>TR</given-names></string-name>, <string-name><surname>Lockyer</surname>
<given-names>JM</given-names></string-name>, et al. <article-title>Human serum biotinidase. cDNA cloning, sequence, and characterization</article-title>. <source/><italic toggle="yes">J Biol Chem</italic>. <year>1994</year>;<volume>269</volume>(<issue>9</issue>):<fpage>6566</fpage>–<lpage>6570</lpage>.<pub-id pub-id-type="pmid">7509806</pub-id></mixed-citation>
</ref>
<ref id="CIT0045">
<label>45.</label>
<mixed-citation publication-type="journal"><string-name><surname>Knight</surname>
<given-names>HC</given-names></string-name>, <string-name><surname>Reynolds</surname>
<given-names>TR</given-names></string-name>, <string-name><surname>Meyers</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Pomponio</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Buck</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <article-title>Structure of the human biotinidase gene</article-title>. <source/><italic toggle="yes">Mamm Genome</italic>. <year>1998</year>;<volume>9</volume>(<issue>4</issue>):<fpage>327</fpage>–<lpage>330</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s003359900760</pub-id><pub-id pub-id-type="pmid">9530634</pub-id></mixed-citation>
</ref>
<ref id="CIT0046">
<label>46.</label>
<mixed-citation publication-type="journal"><string-name><surname>Procter</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Mao</surname>
<given-names>R</given-names></string-name>. <article-title>Forty-eight novel mutations causing biotinidase deficiency</article-title>. <source/><italic toggle="yes">Mol Genet Metab</italic>. <year>2016</year>;<volume>117</volume>(<issue>3</issue>):<fpage>369</fpage>–<lpage>372</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymgme.2016.01.002</pub-id><pub-id pub-id-type="pmid">26810761</pub-id></mixed-citation>
</ref>
<ref id="CIT0047">
<label>47.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <article-title>First microdeletion involving only the biotinidase gene that can cause biotinidase deficiency: a lesson for clinical practice</article-title>. <source/><italic toggle="yes">Mol Genet Metab Rep</italic>. <year>2016</year>;<volume>2</volume>(<issue>6</issue>):<fpage>74</fpage>–<lpage>76</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymgmr.2016.02.006</pub-id></mixed-citation>
</ref>
<ref id="CIT0048">
<label>48.</label>
<mixed-citation publication-type="journal"><string-name><surname>Seker Yilmaz</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Mungan</surname>
<given-names>NO</given-names></string-name>, <string-name><surname>Kor</surname>
<given-names>D</given-names></string-name>, et al. <article-title>Twenty-seven mutations with three novel pathologenic variants causing biotinidase deficiency: a report of 203 patients from the southeastern part of Turkey</article-title>. <source/><italic toggle="yes">J Pediatr Endocrinol Metab</italic>. <year>2018</year>;<volume>31</volume>(<issue>3</issue>):<fpage>339</fpage>–<lpage>343</lpage>. doi:<pub-id pub-id-type="doi">10.1515/jpem-2017-0406</pub-id><pub-id pub-id-type="pmid">29353266</pub-id></mixed-citation>
</ref>
<ref id="CIT0049">
<label>49.</label>
<mixed-citation publication-type="journal"><string-name><surname>Norrgard</surname>
<given-names>KJ</given-names></string-name>, <string-name><surname>Pomponio</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Swango</surname>
<given-names>KL</given-names></string-name>, et al. <article-title>Double mutation (A171T and D444H) is a common cause of profound biotinidase deficiency in children ascertained by newborn screening the the United States</article-title>. <source/><italic toggle="yes">Hum Mutat</italic>. <year>1998</year>;<volume>11</volume>(<issue>5</issue>):<fpage>410</fpage>. doi:<pub-id pub-id-type="doi">10.1002/(SICI)1098-1004(1998)11:5&lt;410::AID-HUMU10&gt;3.0.CO;2-8</pub-id></mixed-citation>
</ref>
<ref id="CIT0050">
<label>50.</label>
<mixed-citation publication-type="journal"><string-name><surname>Sivri</surname>
<given-names>HS</given-names></string-name>, <string-name><surname>Genç</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Tokatli</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Hearing loss in biotinidase deficiency: genotype-phenotype correlation</article-title>. <source/><italic toggle="yes">J Pediatr</italic>. <year>2007</year>;<volume>150</volume>(<issue>4</issue>):<fpage>439</fpage>–<lpage>442</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jpeds.2007.01.036</pub-id><pub-id pub-id-type="pmid">17382128</pub-id></mixed-citation>
</ref>
<ref id="CIT0051">
<label>51.</label>
<mixed-citation publication-type="journal">Desai S, Ganesan K, Hegde A. Biotinidase deficiency: a reversible metabolic encephalopathy. Neuroimaging and MR spectroscopic findings in a series of four patients. <italic>Pediatric Radiology</italic>
<year>2008</year>;<volume>38(8)</volume>:<fpage>848–856</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s00247-008-0904-z</pub-id></mixed-citation>
</ref>
<ref id="CIT0052">
<label>52.</label>
<mixed-citation publication-type="journal"><string-name><surname>Bhat</surname>
<given-names>MD</given-names></string-name>, <string-name><surname>Bindu</surname>
<given-names>PS</given-names></string-name>, <string-name><surname>Christopher</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Prasad</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Verma</surname>
<given-names>A</given-names></string-name>. <article-title>Novel imaging findings in two cases of biotinidase deficiency-a treatable metabolic disorder</article-title>. <source/><italic toggle="yes">Metab Brain Dis</italic>. <year>2015</year>;<volume>30</volume>(<issue>5</issue>):<fpage>1291</fpage>–<lpage>1294</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11011-015-9690-0</pub-id><pub-id pub-id-type="pmid">26037171</pub-id></mixed-citation>
</ref>
<ref id="CIT0053">
<label>53.</label>
<mixed-citation publication-type="journal"><string-name><surname>Raha</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Udani</surname>
<given-names>V</given-names></string-name>. <article-title>Biotinidase deficiency presenting as recurrent myelopathy in a 7-year-old boy and a review of the literature</article-title>. <source/><italic toggle="yes">Pediatr Neurol</italic>. <year>2011</year>;<volume>45</volume>(<issue>4</issue>):<fpage>261</fpage>–<lpage>264</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2011.06.010</pub-id><pub-id pub-id-type="pmid">21907891</pub-id></mixed-citation>
</ref>
<ref id="CIT0054">
<label>54.</label>
<mixed-citation publication-type="journal"><string-name><surname>Weber</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Scholl</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Baumgartner</surname>
<given-names>ER</given-names></string-name>. <article-title>Outcome in patients with profound biotinidase deficiency: relevance of newborn screening</article-title>. <source/><italic toggle="yes">Dev Med Child Neurol</italic>. <year>2004</year>;<volume>46</volume>(<issue>7</issue>):<fpage>481</fpage>–<lpage>484</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1469-8749.2004.tb00509.x</pub-id><pub-id pub-id-type="pmid">15230462</pub-id></mixed-citation>
</ref>
<ref id="CIT0055">
<label>55.</label>
<mixed-citation publication-type="journal"><string-name><surname>Möslinger</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Stöckler-Ipsiroglu</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Scheibenreiter</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Clinical and neuropsychological outcome in 33 patients with biotinidase deficiency ascertained by nationwide newborn screening and family studies in Austria</article-title>. <source/><italic toggle="yes">Eur J Pediatr</italic>. <year>2001</year>;<volume>160</volume>(<issue>5</issue>):<fpage>277</fpage>–<lpage>282</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s004310100740</pub-id><pub-id pub-id-type="pmid">11388594</pub-id></mixed-citation>
</ref>
<ref id="CIT0056">
<label>56.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <article-title>High doses of biotin can interfere with immunoassays that use biotin-strept(avidin) technologies: implications for individuals with biotin-responsive inherited metabolic disorders</article-title>. <source/><italic toggle="yes">Mol Genet Metab</italic>. <year>2019</year>;<volume>127</volume>(<issue>4</issue>):<fpage>321</fpage>–<lpage>324</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymgme.2019.07.003</pub-id><pub-id pub-id-type="pmid">31320189</pub-id></mixed-citation>
</ref>
<ref id="CIT0057">
<label>57.</label>
<mixed-citation publication-type="journal"><string-name><surname>Luong</surname>
<given-names>JHT</given-names></string-name>, <string-name><surname>Male</surname>
<given-names>KB</given-names></string-name>, <string-name><surname>Glennon</surname>
<given-names>JD</given-names></string-name>. <article-title>Biotin interference in immunoassays based on biotin-strept(avidin) chemistry: an emerging threat</article-title>. <source/><italic toggle="yes">Biotechnol Adv</italic>. <year>2019</year>;<volume>37</volume>(<issue>5</issue>):<fpage>634</fpage>–<lpage>641</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biotechadv.2019.03.007</pub-id><pub-id pub-id-type="pmid">30872068</pub-id></mixed-citation>
</ref>
<ref id="CIT0058">
<label>58.</label>
<mixed-citation publication-type="journal"><string-name><surname>Odhaib</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Mansour</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>Haddad</surname>
<given-names>NS</given-names></string-name>. <article-title>How biotin induces misleading results in thyroid bioassays: case series</article-title>. <source/><italic toggle="yes">Cureus</italic>. <year>2019</year>;<volume>11</volume>(<issue>5</issue>):<fpage>e4727</fpage>.<pub-id pub-id-type="pmid">31363424</pub-id></mixed-citation>
</ref>
<ref id="CIT0059">
<label>59.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Heard</surname>
<given-names>GS</given-names></string-name>, <string-name><surname>Jefferson</surname>
<given-names>LG</given-names></string-name>, <string-name><surname>Proud</surname>
<given-names>VK</given-names></string-name>, <string-name><surname>Nance</surname>
<given-names>WE</given-names></string-name>, <string-name><surname>Weissbecker</surname>
<given-names>KA</given-names></string-name>. <article-title>Clinical findings in four children with biotinidase deficiency detected through a statewide neonatal screening program</article-title>. <source/><italic toggle="yes">N Engl J Med</italic>. <year>1985</year>;<volume>313</volume>(<issue>1</issue>):<fpage>16</fpage>–<lpage>19</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM198507043130104</pub-id><pub-id pub-id-type="pmid">4000223</pub-id></mixed-citation>
</ref>
<ref id="CIT0060">
<label>60.</label>
<mixed-citation publication-type="journal"><string-name><surname>Suormala</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Wick</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Baumgartner</surname>
<given-names>ER</given-names></string-name>. <article-title>Low biotinidase activity in plasma of some preterm infants: possible source of false-positive screening results</article-title>. <source/><italic toggle="yes">Eur J Pediatr</italic>. <year>1988</year>;<volume>147</volume>(<issue>5</issue>):<fpage>478</fpage>–<lpage>480</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF00441970</pub-id><pub-id pub-id-type="pmid">3409923</pub-id></mixed-citation>
</ref>
<ref id="CIT0061">
<label>61.</label>
<mixed-citation publication-type="journal"><string-name><surname>Heard</surname>
<given-names>GS</given-names></string-name>, <string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Jefferson</surname>
<given-names>LG</given-names></string-name>, et al. <article-title>Neonatal screening for biotinidase deficiency: results of a 1-year pilot study</article-title>. <source/><italic toggle="yes">J Pediatr</italic>. <year>1986</year>;<volume>108</volume>(<issue>1</issue>):<fpage>40</fpage>–<lpage>46</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0022-3476(86)80766-1</pub-id><pub-id pub-id-type="pmid">3944695</pub-id></mixed-citation>
</ref>
<ref id="CIT0062">
<label>62.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <article-title>Biotinidase deficiency should be considered in individuals thought to have multiple sclerosis and related disorders</article-title>. <source/><italic toggle="yes">Mult Scler Relat Disord</italic>. <year>2019</year>;<volume>28</volume>:<fpage>26</fpage>–<lpage>30</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.msard.2018.11.030</pub-id><pub-id pub-id-type="pmid">30551056</pub-id></mixed-citation>
</ref>
<ref id="CIT0063">
<label>63.</label>
<mixed-citation publication-type="journal"><string-name><surname>Jay</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Conway</surname>
<given-names>RL</given-names></string-name>, <string-name><surname>Feldman</surname>
<given-names>GL</given-names></string-name>, <string-name><surname>Nahhas</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Spencer</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Wolf</surname>
<given-names>B</given-names></string-name>. <article-title>Outcomes of individuals with profound and partial biotinidase deficiency ascertained by newborn screening in Michigan over 25 years</article-title>. <source/><italic toggle="yes">Genet Med</italic>. <year>2015</year>;<volume>17</volume>(<issue>3</issue>):<fpage>205</fpage>–<lpage>209</lpage>. doi:<pub-id pub-id-type="doi">10.1038/gim.2014.104</pub-id><pub-id pub-id-type="pmid">25144890</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>